Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

New oral contrast agent improves bowel disease detection on CT scans

20

Jan 2026

New oral contrast agent improves bowel disease detection on CT scans

In a new pilot feasibility study, researchers from Mayo Clinic, the University of Washington School of Medicine, the University of California San Francisco, and Nextrast Inc. found that a new imaging oral agent, also known as a "contrast agent," helps radiologists better see bowel structures and disease in CT imaging when compared with the current oral contrast agents.

COVID-19 severity is linked to changes in mitochondrial DNA methylation

20

Jan 2026

COVID-19 severity is linked to changes in mitochondrial DNA methylation

This study examined mitochondrial and nuclear-encoded mitochondrial DNA methylation in Indian patients with severe COVID-19 and found region-specific differential methylation linked to disease severity. Pathway analyses and protein assays implicated disrupted mitochondrial metabolism and dynamics, suggesting a role for mitochondrial epigenetic regulation in COVID-19 pathophysiology.

Algae may help meet future protein demand without straining the planet

20

Jan 2026

Algae may help meet future protein demand without straining the planet

This narrative review evaluates clinical evidence on algae and algal proteins as sustainable, nutrient-dense food sources with high protein quality and bioactive compounds. Findings suggest potential benefits for muscle protein synthesis, cardiometabolic markers, immune modulation, and antioxidant status, while emphasizing heterogeneity, short-term data, and the need for longer clinical trials.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.